Pharmacy Pearls: Drug-Induced QTc Prolongation

October 2nd, 2024 | Pharmacy•Cardiology•Pharmacy Pearls

In this edition of Pharmacy Pearls, you will find information on drug-induced QTC prolongation, including which medications are commonly associated with prolonging the QTc interval, what kind of increase might be clinically relevant, and how often you would consider monitoring for QTc prolongation based on a patient’s individualized risk. There is also some guidance on how to manage medication interactions that might increase the risk as well as what to do if your patient should develop drug-induced QTc prolongation.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [202.64 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: Drug-Induced QTc Prolongation

Pharmacy Pearls: Drug-Induced QTc Prolongation

GENERAL COVID-19 INFORMATION